- Record: found
- Abstract: found
- Article: not found
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A Cohen
1 ,
Alasdair J Coles ,
Douglas L Arnold ,
Christian Confavreux ,
Edward J Fox ,
Hans-Peter Hartung ,
Eva Havrdova ,
Krzysztof W Selmaj ,
Howard L Weiner ,
Elizabeth Fisher ,
Vesna V Brinar ,
Gavin Giovannoni ,
Miroslav Stojanovic ,
Bella I Ertik ,
Stephen L Lake ,
David H Margolin ,
Michael A Panzara ,
D Alastair S Compston
Nov 24 2012
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial.